BACKGROUND Although epidemiological studies have reported positive associations between circulating urate levels
U ric acid is the end product of purine metabolism and circulates in the blood as the anion urate. Blood levels of uric acid are causally associated with gout, as implicated by evidence from randomized clinical trials using uratelowering therapies (1) . In 1923, Kylin initially described a constellation of metabolic disturbances that included hypertension, hyperglycemia, and elevated uric acid levels.
Since then, circulating levels of serum uric acid have been reported to be positively correlated with several vascular risk factors including blood pressure, lipids, kidney function, and other metabolic traits (2) . A number of prospective epidemiological studies have associated increased serum uric acid levels and elevated risk for type 2 diabetes mellitus (T2DM) (3), coronary heart disease (CHD) (4-7), ischemic stroke (8, 9) , and heart failure (HF) (10, 11) .
No large-scale intervention studies, however, have evaluated urate-lowering therapies for metabolic and vascular outcomes. In the absence of such evidence, it remains unknown whether circulating uric acid is an independent causal factor for cardiometabolic conditions and whether lowering urate levels might offer therapeutic utility in these disorders.
Human genetic data can be used to directly test the hypothesis of causality between uric acid and clinical endpoints. In particular, Mendelian randomization (MR) studies assess causal inference by using genetic alleles as unbiased proxies for circulating biomarkers (12) . MR studies are based on the random assortment of genetic alleles during meiosis that can confer advantages similar to a randomized controlled trial by investigating the relationship between genetic alleles that are exclusively associated with a biomarker of interest and disease risk (13) . Previously, such an approach has been used to assess the causality of low-and high-density lipoprotein cholesterol (14) , triglycerides (15) , lipoprotein(a) (16, 17) , fibrinogen (18) , and C-reactive protein in CHD (19) . This study's objective is to test the hypothesis that serum urate levels are causally associated with cardiometabolic conditions by applying an MR study design. We integrated information on genetic variants related to serum urate, 50 potential confounders, and risk of disease outcomes. In contrast to previously published genetic reports on serum urateÀrelated genetic variants and disease risk (20) (21) (22) (23) , the current study investigates >10 times more CHD cases and examines, for the first time, risks of stroke and HF conferred by genetically raised serum urate levels. It also systematically evaluates pleiotropy, enabling reliable assessment of any possible moderate causal effect of serum urate levels on any of the 4 major cardiometabolic outcomes. Keenan et al.
METHODS
Causal Assessment of Serum Urate Levels Consortium) (27) Failure studies (Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium) (38) .
DIAGRAM data were downloaded from their website; other data were acquired by contacting investigators within each consortium. We maximized study power by obtaining further data on participants who did not contribute to any of these consortia previously, thus increasing sample size for CHD, ischemic stroke, and HF by up to 25% (Online Table 1 ). Effect sizes and errors from consortia data and study-specific effect sizes and errors from additional studies (Online Table 1 (39, 40) . The impact of the urate genetic score on disease risk was calculated using methods described previously (41, 42) . Briefly, under the assumptions that SNPs are unlinked and the effects of each SNP are log additive on uric acid levels, using an MR framework (12,13), a causal effect (alpha) between a biomarker and outcome can be estimated by
where for all j SNPs, b represents the estimated natural log odds effect of the j-th SNP on the endpoint of interest, s represents the standard error on the log odds effect of the j-th SNP on the endpoint, and w represents a weight for the SNP on the outcome. Each SNP was weighted using the reported estimated effect of the SNP on uric acid levels (in SD units). SE for alpha-hat was calculated by taking the square root of the reciprocal of the denominator, as previously described (42) . A simulation approach was used to estimate the power to identify or exclude causal effects of the urate genetic score on each tested outcome (Online Appendix) (43) . All analyses were Of the 14 urate-specific SNPs, 9 variants were associated with increased risks of gout but none of the variants were associated with T2DM, CHD, ischemic stroke, or HF at a p value <0.01 (Figures 2 and 3 Table 4 ). The variant at the VEGFA locus was significantly associated with decreased risk of T2DM
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(OR: 0.93; 95% CI: 0.89 to 0.96; p ¼ 1.0 Â 10 -4 ) but increased serum urate levels (Online Table 5 ).
URATE GENETIC SCORE AND DISEASE OUTCOMES.
For a 1 SD increase in serum uric acid levels, Of the 28 single nucleotide polymorphisms (SNPs) related to serum urate levels, 14 variants had pleiotropic associations at a p < 0.01 with at least 1 vascular or nonvascular trait. The remaining 14 nonpleiotropic SNPs were used to calculate a genetic score by using individual participant data in the PROMIS (Pakistan Risk of Myocardial Infarction Study) participants. The genetic score was weighted for the reported urate effect estimate of each SNP. The genetic score was subsequently used in analyses with 50 traits in the PROMIS participants and was not found associated with any trait at a p < 0.01. LpPLA2 ¼ lipoprotein-associated phospholipase A2. Table 6 ). A score based on the 14 urate-related variants with pleiotropic effects was also not associated with stroke or HF (Online Table 7 ). However, this score was nominally associated with T2DM, though in a direction opposite of epidemiological expectation, and weakly associated with CHD. We posit that these weak associations are explained by strong, confounding associations of these SNPs with blood pressure, cholesterol, triglycerides, obesity, glucose, insulin, and insulin resistance (Online Table 3 ). These null associations are in contrast to data from observational epidemiological studies which have previously shown that equivalent increases in serum urate levels are associated with increased risks of T2DM For a 1 SD change in serum urate levels due to genetic score, our study was statistically powered at >80% with a 5% alpha rate to assess ORs of 1.15 for T2DM, 1.17 for ischemic stroke, 1.10 for CHD, and 1.24
for HF.
We conducted sensitivity analyses and investigated, in the same study population, the associations of the previously published urate-related SNPs with serum urate levels and CHD risk. In the 7 studies analyzed, we found highly significant associations for uric acid levels by the 3 risk scores that we used in the main analyses earlier (Online Figure 1A) whereas no association was observed between any of the risk scores investigated and CHD risk in the same studies (Online Figure 1B) . We further restricted our analyses to 3 studies in which we investigated the association of: 1) serum urate levels with CHD risk; 2) SNPs with serum urate levels; and 3) SNPs with CHD risk.
Although we found highly significant associations between circulating serum urate levels and CHD risk (Online Figure 2A) and highly significant associations between SNPs and serum urate levels (Online Figure 2B ), no association was observed for any of 3 urate-related GRSs with CHD risk (Online Figure 2C ). Tables 8 to 10 ). rs17786744  rs7976059  rs10480300  rs17632159  rs7224610  rs2941484  rs6770152  rs478607  rs11264341  rs10821905  rs1471633  rs675209  rs2078267  rs12498742   STC1  ACVR1B-L1  PRKAG2  TMEM171  HLF  HNF4G  SFMBT1  NRXN2  TRIM46  A1CF  PDZK1  RREB1  SLC22A11 Keenan et al.
Causal Assessment of Serum Urate Levels rs17786744  rs7976059  rs10480300  rs17632159  rs7224610  rs2941484  rs6770152  rs478607  rs11264341  rs10821905  rs1471633  rs675209  rs2078267  rs12498742   STC1  ACVR1B-L1  PRKAG2  TMEM171  HLF  HNF4G  SFMBT1  NRXN2  TRIM46  A1CF  PDZK1  RREB1  SLC22A11 Of the 14 urate-specific SNPs investigated in association with coronary heart disease, ischemic stroke, and heart failure (HF), none were found associated with any of the above outcomes at a p <0.01. *Data presented from a serum urate genome-wide association study of 48 studies (n = 110,347) (39) . CHD ¼ coronary heart disease; other abbreviations as in Keenan et al. Causal Assessment of Serum Urate Levels
Our findings were consistent with a prior report that evaluated variation at the SLC2A9 gene in association with ischemic heart disease that found no evidence of an association between genetically lowered uric acid and CHD or blood pressure (21) . The current study extended these prior findings by evaluating all variants associated with uric acid systematically, exploring pleiotropy for all uric-acid related variants, investigating other cardiometabolic outcomes (i.e., T2DM, stroke, and HF), and assessing >7-fold more CHD cases (54,501 in the current report vs. 7,172 in the prior report). Thus, it provided an analysis adequately powered to assess urate variants and genetic scores known to have modest effects on urate levels.
We observed that one serum urate SNP in the ATXN2 gene, which was pleiotropic for major lipid, glycemic, and anthropometric traits (thus excluded from our score-based MR analysis), appeared to be associated with risks of CHD and ischemic stroke at nominal levels of significance. This SNP is located in a high-frequency (w40%) long-range (1.6 Mb) haplotype, previously described to be associated with a range of other traits including type 1 diabetes, celiac disease, and elevated platelet counts. This haplotype is speculated to have arisen from a selective sweep specific to Europeans w3,400 years ago when highdensity human settlements were expanding in that region of the world (33) . In analyses restricted to participants of South Asian ancestry, we did not find this variant to be associated with major lipids in 37,000 participants or with risks of CHD (9,000 cases and 9,000 controls) or ischemic stroke (3,500 cases and 5,000 controls). Because of the high pleiotropic nature of this locus and specificity to populations of European ancestry, it is unlikely that the ATXN2 locus leads to CHD by increasing serum urate levels.
STUDY LIMITATIONS. Potential limitations of this study should be considered. First, while analyses on HF in the current study were underpowered (Online Table 9 ), the concordance of the null findings observed for all cardiometabolic outcomes tend to suggest a lack of a major etiological role of serum urate levels in HF. Second, we evaluated only 50 traits to assess pleiotropy for uric acid SNPs and did not conduct measurements for all possible biological traits; however, we conducted analyses using both single SNPs and a GRS in association with cardiometabolic outcomes. Importantly, we also conducted analyses for a variant, rs12498742, that imparts the strongest effect on uric acid levels (Online Table 10 ) and is located in an intron of the SLC2A9
gene that encodes for a glucose and urate transporter in the kidney, hence providing biological plausibility to our hypothesis. We did not find this variant to be associated with any other trait apart from circulating urate levels; hence enabling MR analyses using this variant only. We did not find rs12498742 to be associated with any cardiometabolic outcome despite the fact that MR analyses with this variant were sufficiently powered (Online Table 9 ).
Third, nonpleiotropic variants in addition to the SLC2A9 variant explained only 15.3% of the variance in serum urate levels (Online Table 10 ). However, none of them were associated with any of the investigated cardiometabolic endpoints in our large-scale analyses, casting further doubt on serum urate as a causal factor. Fourth, as suggested by our power calculations (Online Table 9 ), although we were able to exclude effects imparted by a 1 SD change in serum urate levels on disease risk, which are weak to modest and consistent with prior epidemiological studies (3-11) (Online Table 9 ), our analyses may not have detected very weak disease risk estimates (e.g., OR
for CHD < 1.10).
Fifth, while our assessment of causality was limited to SNPs that are observed to be non- 
